Zynex Inc. Announces Proposed Public Offering of Common Stock

Rhea-AI Summary

Zynex, a medical technology company, announced a public offering of its common stock. The offering involves Zynex and certain stockholders proposing to sell shares, with a 30-day option for underwriters to purchase additional shares. Funds from the offering will be used to expand the sales force, marketing efforts, and launch a new blood volume monitor. The offering is subject to market conditions, and Zynex will not receive proceeds from sales made by stockholders. Piper Sandler is the sole book-running manager for this offering.

Positive

• Intended use of funds includes expanding sales force and marketing activities.
• Launch of a new blood volume monitor could contribute to future growth.

Negative

• The proposed offering could lead to shareholder dilution.
• Market conditions could affect the completion and size of the offering.

ENGLEWOOD, Colo., July 14, 2020 /PRNewswire/ -- Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it is commencing an underwritten public offering of shares of its common stock. Zynex and certain of its stockholders are proposing to sell shares of its common stock in the proposed offering.  In addition, Zynex and the selling stockholders intend to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Zynex intends to use the net proceeds from this proposed offering to expand its sales force and marketing activities, launch its blood volume monitor, as well as for working capital and other general corporate purposes, including potential corporate, business or market development activities. Zynex will not receive any proceeds from the sale of the shares by the selling stockholders in the proposed offering.

Piper Sandler & Co. is acting as sole book-running manager of the proposed offering. 

The proposed offering will be made pursuant to the shelf registration statement on Form S-3 (File No. 333-230128) that was filed with the Securities and Exchange Commission (the "SEC") and became effective on March 12, 2019, and the shelf registration statement on Form S-3 (File No. 333-232367) that was filed with the SEC and became effective on July 3, 2019, for the shares of common stock being offered by Zynex and the selling stockholders, respectively (together, the "registration statements"). The proposed offering will be made only by means of written prospectuses and prospectus supplements that form part of such registration statements. Preliminary prospectus supplements and accompanying prospectuses relating to and describing the terms of the proposed offering have been filed with the SEC and are available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplements and accompanying prospectuses may also be obtained for free from the offices of Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation. Zynex's proprietary NeuroMove device is designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers.  For additional information, please visit: -1%26h%3D1180415947%26u%3Dhttp%253A%252F%252Fwww.zynex.com%252F%26a%3DZynex.com&a=Zynex.com" rel="nofollow">Zynex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Zynex's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, forecasts, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Zynex's control. Zynex's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.  Zynex makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, Zynex's dependence on the reimbursement for its products from health insurance companies, Zynex's dependence on third party manufacturers to produce its goods on time and to its specifications, implementation of Zynex's sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in Zynex's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2019 as well as its quarterly reports on Form 10-Q and current reports on Form 8-K.

Any forward-looking statement made by Zynex in this press release is based only on information currently available to Zynex and speaks only as of the date on which it is made. Zynex undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact

Zynex, Inc.
(303) 703-4906

View original content to download multimedia:http://www.prnewswire.com/news-releases/zynex-inc-announces-proposed-public-offering-of-common-stock-301093437.html

SOURCE Zynex

FAQ

What is the purpose of Zynex's public offering of common stock?

Zynex aims to use the net proceeds to expand its sales force and marketing efforts, as well as to launch a new blood volume monitor.

Who is managing Zynex's proposed public offering?

Piper Sandler is acting as the sole book-running manager for Zynex's offering.

How might the public offering affect Zynex shareholders?

The offering may lead to dilution of existing shares.

What options do underwriters have in Zynex's public offering?

Underwriters have a 30-day option to purchase additional shares at the public offering price.

When was the public offering announced?

The public offering was announced on July 14, 2020.